A study published in the August issue of the journal Brain demonstrates, for the first time, an association between increased white matter volume and functional impairment in children with autism.
Today, Mayo Clinic opened the wall of one of its hospitals and used a crane to slide in a huge, high-tech steel box designed to heal patients and foster medical discoveries. The box is a 3,800-cubic-foot, high-pressure hyperbaric system that contains three specialized therapy rooms.
The world?s most common joint disease, osteoarthritis (OA) affects more than 10 percent of American adults, nearly 80 percent of people past age 55, and about three times as many women as men.
The use of steroid medication to treat bronchiolitis ? a common viral lower respiratory infection in infants ? does not prevent hospitalization or improve their respiratory symptoms, according to a study published in the July 26 issue of The New England Journal of Medicine.
National Jewish Medical and Research Center discharged patient Andrew Speaker at 6 a.m. Thursday, July 26, after the successful completion of his in-patient treatment for multi-drug-resistant tuberculosis.
As of midnight July_19, 2007, the Medicare Advantage contract between the Centers for Medicare and Medicaid Services (CMS) and America?s Health Choice, Inc. (AHC) of Vero Beach, Florida is terminated.
This is an analysis of existing data that has been previously published (online in Diabetes Care, 29 May 2007) and provides no new information on the risk of heart failure associated with the thiazolinediones (TZD) class.
Using a quantitative high-throughput screening strategy, researchers at the National Institutes of Health (NIH) have identified three new classes of small molecules that may prove useful for treating Gaucher disease, an inherited disorder that disrupts a cell?s ability to break down and dispose of certain cellular waste products.
The U.S. Food and Drug Administration announced that it is permitting the restricted use of Zelnorm (tegaserod maleate) under a treatment investigational new drug (IND) protocol to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in women younger than 55 who meet specific guidelines.
On July_24, 2007 the U.S. Food and Drug Administration (FDA) was informed by Targeted Genetics Corporation of Seattle about the death of a patient who received an investigational gene therapy product in a clinical trial for the treatment of active inflammatory arthritis.